Moleculin Biotech Inc. Common Stock (MBRX)

FairStock Score: 68/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I begin with the business. Moleculin is a clinical-stage biotech with 17 employees, no revenue in the filed periods, and a pipeline led by Annamycin for relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases, plus the WP1066 portfolio. That is a speculative research effort, not a proven enterprise with a moat. The financials confirm the risk: in fiscal Q2 2026, the quarter ended 2026-06-30, net income was -$7.6M; in fiscal Q1 2026, the quarter ended 2026-03-31, net income was -$12.8M; in FY2025, the year ended 2025-12-31, net income was -$33.6M; in FY2024, the year ended 2024-12-31, net income was -$26.0M; and in FY2023, the year ended 2023-12-31, net income was -$29.8M. Trailing free cash flow is -$25.4M, a FairStock figure, against an $8.5M market cap. That is a -299.3% FCF yield, meaning the company burns several times its market value annually. Yes, the FairStock P/B is 0.27 and D/E is 0.03, and a Graham Number of $23.13 with a 98.12% margin of safety is listed. But those calculations are unreliable when there are no earnings, and filed statements show negative diluted EPS in every listed period. The Piotroski F-Score is 1/9 and Altman Z-Score is -14.54, both pointing to distress. The Lynch category is none because of losses in each of the last four years. The stock at $0.44 on 2026-10-13 may be a lottery ticket on clinical success, but I see no durable earnings, no margin of safety in the Graham sense, and no predictable growth. I would pass.

In plain English: Moleculin Biotech is a tiny drug developer with no product sales yet. It is testing cancer and virus treatments, but it loses money every year and spends more cash than its entire stock market value. The 44-cent share price may look cheap on some backward-looking measures, but the business itself is very weak and hard to value without sales or profits.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer